SCHEMBL5282082

SCHEMBL5282082

COc1cc(NS(=O)(=O)c2ccc(Cl)c3nonc23)c(OC)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
NPSR1 Q6W5P4 3/20 0.61
TP53 P04637 3/20 0.61
TSHR P16473 2/20 0.61
USP2 O75604 1/20 0.61
RAB9A P51151 1/20 0.61
MAPK1 P28482 2/20 0.58
LMNA P02545 2/20 0.52
HTT P42858 1/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 1/20 0.51
BRD4 O60885 3/20 0.48
POLB P06746 1/20 0.47
RORA P35398 1/20 0.47
RORC P51449 1/20 0.47
NR1H2 P55055 1/20 0.47
PFKFB3 Q16875 1/20 0.44
ALPL P05186 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5288457 0.91 ALDH1A1 (0.53) ALDH1A1NPSR1TP53TSHRUSP2
SCHEMBL5242589 0.90 ALDH1A1 (0.58) ALDH1A1NPSR1TP53TSHRUSP2
SCHEMBL5243631 0.90 ALDH1A1 (0.58) ALDH1A1NPSR1TP53TSHRUSP2
SCHEMBL5299209 0.87 MEN1 (0.58) ALDH1A1NPSR1TP53TSHRUSP2
SCHEMBL5243619 0.86 ALDH1A1 (0.69) ALDH1A1NPSR1TP53TSHRUSP2
SCHEMBL5288031 0.86 ALDH1A1 (0.57) ALDH1A1NPSR1TP53TSHRUSP2
SCHEMBL5244715 0.84 NPC1 (0.55) ALDH1A1TSHRMAPK1LMNAHTT
SCHEMBL5281788 0.81 ALDH1A1 (0.50) ALDH1A1NPSR1TP53TSHRUSP2
SCHEMBL5296878 0.81 ALDH1A1 (0.49) ALDH1A1NPSR1TP53TSHRUSP2
SCHEMBL4805366 0.78 GHSR (0.70)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP ALDH1A1 2627/4885NPSR1 4508/4885TP53 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.